LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm
LSB Industries, Inc. Schedules 2025 Third Quarter Results Release for Wednesday, October 29th and Conference Call for Thursday, October 30th
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
LSB Industries, Inc. to Participate in Upcoming Investor Conferences
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
LSB Industries, Inc. Reports Operating Results for the 2025 Second Quarter
LSB Industries, Inc. Schedules 2025 Second Quarter Results Release for Tuesday, July 29th and Conference Call for Wednesday, July 30th
LakeShore Biopharma Announces US$15 Million Private Placement Financing
LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th
LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th
LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors
LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025
LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
LSB Industries Announces Publication of 2023 Sustainability Report
LSB Industries, Inc. Appoints John Chandler as an Independent Member of the Board of Directors
LSB Industries, Inc. Reports Operating Results for the 2024 Third Quarter
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
LSB Industries, Inc. Schedules 2024 Third Quarter Financial Results Release for Tuesday, October 29th and Conference Call for Wednesday, October 30th
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
LakeShore Biopharma Announces Leadership Transitions
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition